Mayne Pharma Group (ASX:MYX) said the Australian Pharmaceutical Benefits Scheme (PBS) approved the reimbursement of oral contraceptive Nextstellis, according to a Monday filing with the Australian bourse.
Nextstellis will be listed on the PBS General Schedule from October, the filing said.
Shares rose nearly 1% in morning trade on Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.